Skip Navigation



Annals of Oncology Advance Access published online on December 19, 2005
Annals of Oncology, doi:10.1093/annonc/mdj100
This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
17/5/735    most recent
mdj100v1
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Hennenfent, K. L.
Right arrow Articles by Govindan, R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hennenfent, K. L.
Right arrow Articles by Govindan, R.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2005 European Society for Medical Oncology
Received August 13, 2005
Revised November 5, 2005
Accepted November 7, 2005

review

Novel formulations of taxanes: a review. Old wine in a new bottle?

K. L. Hennenfent 1 and R. Govindan 2 *

1 St Louis College of Pharmacy, Ortho Biotech Clinical Affairs, LLC, St Louis, MO, USA
2 Alvin J Siteman Cancer Center, Washington University School of Medicine, St Louis, MO, USA

* To whom correspondence should be addressed.
R. Govindan, E-mail: rgovinda{at}im.wustl.edu


  Abstract

Over the past two decades, the taxanes have played a significant role in the treatment of various malignancies. However, the poor solubility of these compounds necessitates the inclusion of surfactant vehicles in their commercial formulations. Cremophor EL and polysorbate 80 have long comprised the standard solvent system for paclitaxel and docetaxel, respectively. A number of pharmacologic and biologic effects related to both of these drug formulations have been described, including clinically relevant acute hypersensitivity reactions and peripheral neuropathy. In addition, these solvents affect the disposition of intravenously administered solubilized drugs and leach plasticizers from polyvinylchloride infusion sets. A number of strategies to develop formulations of surfactant-free taxanes have been developed. They include albumin nanoparticles, polyglutamates, taxane analogs and prodrugs, emulsions, and lipsomes. An overview of these novel formulations of taxanes, their mechanisms of action, pharmacokinetics, dose and administration, adverse effects, and clinical efficacy will be discussed.

Keywords: novel formulations; taxanes; vehicles.
Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Am J Health Syst PharmHome page
S. Goodin
Novel cytotoxic agents: Epothilones
Am. J. Health Syst. Pharm., May 15, 2008; 65(10_Supplement_3): S10 - S15.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
N. Wiedenmann, D. Valdecanas, N. Hunter, S. Hyde, T. A. Buchholz, L. Milas, and K. A. Mason
130-nm Albumin-Bound Paclitaxel Enhances Tumor Radiocurability and Therapeutic Gain
Clin. Cancer Res., March 15, 2007; 13(6): 1868 - 1874.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
D. Goldstein, O. Gofrit, A. Nyska, and S. Benita
Anti-HER2 Cationic Immunoemulsion as a Potential Targeted Drug Delivery System for the Treatment of Prostate Cancer
Cancer Res., January 1, 2007; 67(1): 269 - 275.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.